Radiant Biotherapeutics, a Toronto-based pre-clinical biotechnology startup developing an advanced antibody platform to offer life-changing therapies for patients with life-threatening diseases, has secured $35 million in Series A funding round to fuel growth and advance its platform for clinics.
Led by Arthur Fratamico and Jo Hulme, the company’s platform offers diverse biologics to help fight difficult-to-treat illnesses such as infectious diseases, auto-immune, and cancer, allowing healthcare professionals to unlock cures for patients.
The funding round was led by Amplitude Ventures and the Bill & Melinda Gates Foundation with significant contributions from BDC Capital, the investment wing of the Business Development Bank of Canada, and abrdn Inc.’s managed abrdn.
Existing investors Alexandria Venture Investments, Toronto Innovation Acceleration Partners (TIAP), and FACIT also joined the round.
Radiant Biotherapeutics Platform
Radiant has developed a proprietary multi-purpose antibody platform called Multabody™, designed to overcome the shortfalls of existing anti-body approaches by leveraging remarkable binding strength on their targets.
The platform also leverages multi-specificity to allow the targeting of a wide range of disease-altering proteins and multiple epitopes on a single target. Multabody’s multi-specificity and multi-valiant qualities give it remarkable potency against infectious disease pathogens, blood cancers, and solid tumors, as well as other specific targets in many therapeutic areas.
The new funding will support further advancement of 4-1BB, the company’s lead clinical candidate, and propel it to clinical trials.
